Dedalus acquires Dosing, a leading SaaS medication safety solutions provider
Dedalus Group, a leading international healthcare software solutions provider has acquired Dosing GmbH, a leading provider of digitised Software-as-a-Service (SaaS) medication safety solutions.
This acquisition extends Dedalus’ portfolio to include specialised solutions to support medical decision-makers and patients along the entire medication process - from therapy recommendation and prescribing to administration and use directions.
Andrea Fiumicelli, CEO of Dedalus Group, said: "Dosing brings solutions and capabilities that are essential for the digital transformation of the healthcare ecosystem - the core of our vision. We believe that clinically relevant content, such as medication safety information, is central to ensuring the highest quality and safety of care through the Clinical Decision Support (CDS) solutions within our portfolio."
Michael Dahlweid, Chief Product Officer for Dedalus Group further commented: “We are really excited to bring Dosing into our organisation. Their solutions provide sophisticated and complex medication capabilities that are characterised both by their scope and expertise. Following this acquisition, we are aware of our obligations to Dosing's partners and will ensure that Dosing will continue to work and cooperate with all of them."
Winfried Post, DACH General Manager and member of Dedalus Executive Committee, added: "Today, Dosing’s solutions are being used successfully in more than 270 hospitals, mainly in Germany. This acquisition is an important step to complement our content provider offering in Germany, Austria and Switzerland."
Jens Kaltschmidt, CEO of Dosing, said: "We develop state-of-the-art software to enable safe medication processes. For us, 'Ease of use' is as important as data quality and accurate process integration. Globally recognised academic institutions support us, and our team of experts works hand in hand with renowned business partners. What drives us is the safety and well-being of each and every patient."
Dedalus is owned by the largest European private equity firm Ardian.
For more on Dedalus, click here
For more on Dosing, click here